Abstract: A tube for a heat exchanger is disclosed, the tube including a plurality of protuberances formed on an inner surface of the tube. The protuberances are arranged in a pattern that maintains a substantially constant cross sectional hydraulic area along a length of the tube.

Abstract: The present invention provides a method for accurately determining the likelihood that a subject will respond to treatment with an immunomodulatory composition comprising detecting one or more markers in a sample from the subject, wherein at least one markers is linked to a single nucleotide polymorphism (SNP) set forth in Table 1 or 3-5, and processes for selecting suitable subjects for therapy or for continued therapy, and for providing appropriate therapy to subjects, based on the assay results.

Abstract: The present invention provides a method for accurately determining the likelihood that a subject will respond to treatment with an immunomodulatory composition comprising detecting one or more markers in a sample from the subject, wherein at least one markers is linked to a single nucleotide polymorphism (SNP) set forth in Table 1 or 3-5, and processes for selecting suitable subjects for therapy or for continued therapy, and for providing appropriate therapy to subjects, based on the assay results.

Abstract: A tube for a heat exchanger is disclosed, the tube including a plurality of protuberances formed on an inner surface of the tube. The protuberances are arranged in a pattern that maintains a substantially constant cross sectional hydraulic area along a length of the tube.

Abstract: An extruded tube for a heat exchanger is disclosed, the tube including a plurality of deformations formed therein, wherein the deformations of the extruded tube facilitates a maximization of a thermal efficiency of the heat exchanger.

Abstract: It is disclosed herein that particular forms of MS have significant pathogenetic differences both between each other and when compared to controls. In particular, CD127 is under-expressed in one form of MS but over-expressed in another form, relative both to each form of MS and to controls. Methods and compositions are provided for the treatment and/or diagnosis of disease caused by forms of multiple sclerosis that under-express and forms that over-express CD127. In specific examples, the methods for treating CD127-low MS comprise administering an effective amount of IL-7 or an effective amount of leukocytes treated with IL-7. Also provided are methods for treating CD127-low MS wherein leukocytes are induced to express at least one receptor, a subunit of which is CD127.